- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Interventions
- Maridebart Cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 45 Years to 99 Years
- Enrollment
- 12,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 140
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 117 more
Location Directory
Clinical trials in Columbus, Ohio
This page shows live ClinicalTrials.gov search results for Columbus, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10863
Shown on this page
12
Current sort
Recently updated
Location scope
Columbus, OH
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 709–720 of 10,863 matching trials in Columbus, OH.
Live ClinicalTrials.gov results.
Institutions in Columbus
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Dravet Syndrome
- Interventions
- Clemizole HCl, Placebo
- Drug
- Lead sponsor
- Epygenix
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 43
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 37 more
- Conditions
- Malignant Solid Neoplasm
- Interventions
- Best Practice, Financial Navigation, Interview, Survey Administration
- Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- Not listed
- Enrollment
- 760 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 383
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 252 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab, MK-4830, MK-0482
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
- Conditions
- Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
- Interventions
- Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
- Drug · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
- Conditions
- Stage II Prostate Adenocarcinoma AJCC v7
- Interventions
- Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 276
- States / cities
- Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
- Conditions
- Smoking (Tobacco) Addiction
- Interventions
- Reduced Nicotine Content Cigars, Normal nicotine content cigar, Usual brand cigar
- Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Relapsed and/or Refractory B-cell Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, KITE-363, KITE-753
- Drug · Biological
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Duarte, California • Stanford, California + 17 more
- Conditions
- Endometriosis
- Interventions
- Observational study, no intervention
- Other
- Lead sponsor
- Aspira Women's Health
- Industry
- Eligibility
- 14 Years to 50 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Burbank, California • Newark, Delaware + 7 more
- Conditions
- Ureteral Diseases
- Interventions
- Uriprene® Degradable Temporary Ureteral Stent
- Device
- Lead sponsor
- Adva-Tec
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 1 more
- Conditions
- Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 0 Minutes to 2 Weeks
- Enrollment
- 8,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 48 more